Target Audience
This program is intended for all surgeons who are involved in the treatment of patients with cancer.

Goals
The goals of this symposium are to: (1) present current approaches, developing innovations, and ongoing controversies in cancer management; and (2) contribute to the knowledge of surgeons as participants in multidisciplinary teams dedicated to the care of cancer patients.

Educational Objectives
Upon completion of this program, participants should be able to: 1) discuss the interdisciplinary management of breast cancer with an emphasis on targeted and systemic therapies, advances in surgical therapies such as lymphatic mapping and radiation therapy controversies; 2) describe the status of minimally invasive surgery in cancer care; 3) explain the evidence and controversial applications of CT/PET imaging in oncology; 4) discuss the role of molecular targeted cancer therapies; 5) describe how the practicing oncologist can become involved in clinical research; 6) describe the recent results from NIH funded cooperative group trials; and 7) explain the best practice for colon cancer screening prevention and management.

Accreditation
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The SSO takes responsibility for the content, quality and scientific integrity of this CME activity.

SSO designates this educational activity for a maximum of 33.75 category 1 credits toward the AMA Physician's Recognition Award.

Each physician should claim only credits that he/she actually spent in the educational activity.

Accommodations and Attractions
The San Diego Marriott Hotel & Marina is the headquarters hotel and will house the entire meeting including all scientific sessions and exhibits. The San Diego Marriott, located at the water’s edge, offers a superior level of service in a lush resort setting. It’s ideally located adjacent to Seaport Village and features several restaurants and lounges, room service, and a state-of-the-art fitness center.

The San Diego Marriott is a 10 minute cab ride from San Diego International Airport.

Hotel reservations must be made through the PassKey Reservations System via the internet (www.surgonc.org) or by phone. A credit card will be required to guarantee your reservation.

For best availability, make your reservation via the internet at www.surgonc.org. You may also make reservations by calling (800) 266-9432. Any changes / cancellations to your reservation must be made through the PassKey Reservations System either by the internet or by phone through February 27, 2006. Please do not call the hotel directly as they will not have access to the SSO room block, PassKey Reservations System or the group rate until after February 27, 2006.

The deadline for reservations is Monday, February 27, 2006.

Hotel reservations / rate availability are not guaranteed after the room block is full or after February 27, 2006. Please register early – only a limited number of rooms are available at the hotel.

Special Airfare Discounts
SSO has arranged with United Airlines for special discounts on airfares to San Diego. Save up to 15% when your tickets are purchased at least 30 days in advance. Travel must take place between March 18-31, 2006 and some restrictions may apply. Please mention the SSO Meeting ID number (listed below) when making your airline reservations.

To book your reservation, call SSO's official travel agency, Uniglobe Preferred Travel, at 1-800-626-0359 and after the prompt dial “0” (M-F 8:30 am – 5:30 pm CST).

If you prefer you may:
• Book your travel online at www.uniglobepreferred.com. Scroll down and click on Rapid-Rez icon.
When the booking page comes up, click on
Scientific Program Chairman’s Message

On behalf of SSO President Dr. Timothy Eberlein, the Executive Council and the Scientific Program Committee, I invite you to attend the 59th Annual Cancer Symposium of the Society of Surgical Oncology, March 23-26, 2006 in San Diego, California.

Controversies, standards, and emerging innovations are the focus for this year’s scientific meeting. From the role of molecular signatures in breast cancer to cine videos on endosurgery in gastrointestinal cancer, the future is the target for the podium. This year’s scientific program committee has done a fine job of providing a balanced perspective on topics of interest from the latest in laboratory research to the most practical in clinical standards. The program is complemented by excellent invited speakers, podium and poster abstracts, educational symposiums, and Meet-the-Professor Breakfasts.

We are honored to have an exceptional group of invited speakers, including: Bruce Stillman, M.D., American Cancer Society Lecture; James Economou, M.D., James Ewing Lecture; and Murray F. Brennan, M.D., John Wayne Clinical Research Lecture. Dr. Charles M. Balch will be honored with the Annual Heritage Award.

A record-high 489 abstracts were reviewed by specialty-based committees with 103 chosen for oral presentation and 230 selected for poster presentation. The quality was excellent; a lot to look forward to at this year’s meeting. A visual tour of technical aspects of laparoscopic surgery for cancer is a highlight of this year’s cine clinic.

Several excellent educational symposia and world-renowned Professors have been included in the program to encourage focused discussions on topics of interest to surgical oncologists. Finally, sessions on “Clinical Trial Highlights – 2006” and “Clinical Research and the Practicing Oncologist” should stimulate dialogue on better ways to engage community surgeons in NCI-sponsored cancer trials.

We look forward to seeing you in San Diego.

Sincerely,

Heidi Nelson, M.D.
Chair, Scientific Program Committee
Breakfast Symposium

Advances in the Systemic Therapy and Surgical Management of Breast Cancer
6:00 – 8:00 am

Moderator: Lisa A. Newman, MD

Welcome and Overview - Expanding and Refining Non-Operative Therapy or Breast Cancer: Where Does the Surgical Oncologist Fit In?
Lisa A. Newman, MD
University of Michigan
Ann Arbor, MI

Systemic and Targeted Therapy for Breast Cancer: The Role Oncotyping, Herceptin, and Aromatase Inhibitors
Debu Tripathy, MD
University of Texas Southwestern Medical Center
Dallas, TX

Hiram S. Cody, III, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

NSABP Perspective on Neoadjuvant versus Adjuvant Chemotherapy
Terry P. Mamounas, MD, MPH
Aultman Cancer Center
Canton, OH

Controversial Issues in Radiation Therapy for Breast Cancer
Thomas Buchholz, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

Panel Discussion

Symposium

Molecular Targeted Cancer Therapies
8:00 – 10:00 am

Moderator: Kelly M. McMasters, MD, PhD

Welcome and Introduction
Kelly M. McMasters, MD, PhD
University of Louisville
Louisville, KY

Anti-angiogenic Targets for Cancer Therapy
Lee M. Ellis, MD, PhD
University of Texas, M.D. Anderson Cancer Center
Houston, TX

Targeting Her2/Neu for Breast Cancer Therapy
George Sledge, MD
Indiana University School of Medicine
Indianapolis, IN

EGFR as a Molecular Target for Cancer Therapy
Roman Perez-Soler, MD
New York University School of Medicine
New York, NY

In the Pipeline: New Prospects for Targeted Cancer Therapy
Edward A. Sausville, MD, PhD
University of Maryland Greenebaum Cancer Center
University of Maryland School of Medicine
Baltimore, MD

Discussion
Minimally Invasive Cancer Surgery – State of the Science

8:00 – 10:00 am

Moderator: Martin R. Weiser, MD

Primary Ablation of Breast Lesions
Rache M. Simmons, MD
Associate Professor of Surgery
Weill Medical College of Cornell University
New York, NY

Current Role of Laparoscopic Pancreatectomy
Attila Nakeeb, MD
Associate Professor of Surgery
Indiana University School of Medicine
Indianapolis, IN

Minimally Invasive Rectal Resection
Martin R. Weiser, MD
Assistant Surgeon, Memorial Sloan-Kettering Cancer Center; Assistant Professor of Surgery, Weill Medical College of Cornell University
New York, NY

Laparoscopic and Robotic Approaches to Prostatectomy
Peter G. Schulam, MD, PhD
Associate Professor, Department of Urology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Symposium

CT-PET Imaging: Evidence-Based Indications and Controversies

10:30 am - Noon

Moderator: Seza A. Gulec, MD

Introduction
Seza A. Gulec, MD

Principles of Current Technology
Edward Coleman, MD
Duke University Medical Center
Durham, NC

Clinical Applications Pros and Cons:

Melanoma
Douglas J. Schwartzentruber, MD
Center for Cancer Care at Goshen Health System
Goshen, IN

Breast
David J. Winchester, MD
Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare
Evanston, IL

Gastrointestinal
Jose Guillem, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Future Technologies
Richard Wahl, MD
Johns Hopkins PET Center
Baltimore, MD

PET Imaging as a Tumor Marker
Seza A. Gulec, MD
Center for Cancer Care at Goshen Health System
Goshen, IN
Breast Cancer Evolving Research and Practice Patterns

10:30 am - Noon

Moderator: Henry M. Kuerer, MD, PhD

Post-mastectomy Radiation and the Surgical Oncologist: Implications for Reconstruction
Steven Kronowitz, MD
University of Texas, M.D. Anderson Cancer Center
Houston, TX

Preoperative Treatment for DCIS
E. Shelley Hwang, MD
University of California San Francisco
San Francisco, CA

Onco-type DX: Is There Any Clinical Utility?
Terry Mamounas, MD, MPH
Aultman Hospital
Canton OH

Integrating Recent Landmark Systemic Therapy Data into Clinical Practice: What the Surgeon Needs to Know
William J. Gradishar, MD
Northwestern University
Chicago, IL

Foregut Cancer – Evolving Research and Practice Interests

1:00 - 3:00 pm

Moderator: Mitchell C. Posner, MD

Introduction
Mitchell C. Posner, MD
Professor and Chief
University of Chicago
Chicago, IL

Population Sciences Update:
Improving the Outcomes of Esophageal, Gastric and Pancreatic Cancer
John D. Birkmeyer, MD
GD Zuidema Professor of Surgery
University of Michigan
Ann Arbor, MI

Adjuvant Therapy, Neoadjuvant Therapy or Resection Only:
Gastric and Esophageal Cancer
David H. Ilson, MD
Associate Professor, Cornell University Medical College and Associate Attending, Memorial Sloan-Kettering Cancer Center
New York, NY

Pancreatic Cancer
Peter W.T. Pisters, MD
Professor of Surgery
University of Texas, M.D. Anderson Cancer Center
Houston, TX

Minimally Invasive Surgery for Foregut Cancer – Is it the Future?
Minimally Invasive Approaches to Esophageal and Gastric Cancer
Yuko Kitagawa, MD
Assistant Professor
Keio University School of Medicine
Tokyo, Japan

The Role of Endosurgery in Foregut Cancer – The Future Has Arrived
Irving Waxman, MD
Professor of Medicine, Surgery and the Cancer Research Center; Director of Endoscopy, University of Chicago
Chicago, IL
Clinical Research and the Practicing Oncologist

1:00 - 3:00 pm
Moderator: Terry Mamsunus, MD and Peter W.T. Pisters, MD

Becoming an NCI-Approved Clinical Investigator
Margaret M. Mooney, MD
National Cancer Institute
Bethesda, MD

Working With Your IRB
Scott H. Kurtzman, MD
University of Connecticut Health Center
Farmington, CT

Maintaining a Research Program of the Highest Quality
Walt Cronin, MPH
NSABP Biostatistical Center
Pittsburgh, PA

Implementing Clinical Research in a Private Practice Setting
Thomas G. Frazier, MD
Bryn Mawr Hospital
Bryn Mawr, PA

Discussion

Symposium

Advances in Nutritional Support of the Surgical Cancer Patient

3:30 - 5:30 pm
Moderator: John M. Daly, MD

Introduction – “Brief History of Immunonutrition”
John M. Daly, MD
Professor of Surgery and Dean
Temple University School of Medicine
Philadelphia, PA

Kenneth Kudsk, MD
Professor of Surgery
Vice Chairman of Surgical Research
University of Wisconsin
Madison, WI

Role of Arginine in the Care of the Surgical Patient
Adrian Barbul, MD
Surgeon-in-Chief and Professor of Surgery
Sinai Hospital, Johns Hopkins University
Baltimore, MD

Clinical Trials of Immunonutrition in Surgical Cancer Patients
Marco Braga, MD
Professor of Surgery
University of Milan, San Raffaele Hospital
Milan, Italy

Discussion
**Controversies in Surgical Oncology: Can We Define an Evidence Based Standard of Care?**

3:30 - 5:30 pm

*Moderator: Daniel G. Coit, MD*

**Multimodality Therapy is NOT the Standard of Care for Adenocarcinoma of the GE Junction**

*Pro:* Tom R. DeMeester, PhD
University of Southern California, Los Angeles, CA

*Con:* Mitchell C. Posner, MD
University of Chicago, Chicago, IL

**The Optimal Margin of Resection for All Melanomas is 1 cm**

*Pro:* Vernon K. Sondak, MD
H. Lee Moffitt Cancer Center, Tampa, FL

*Con:* Merrick I. Ross, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

**Completion Axillary Lymph Node Dissection is Unnecessary for Sentinel Node Positive Breast Cancer**

*Pro:* Blake Cady, MD
Rhode Island Hospital, Providence, RI

*Con:* Kelly M. McMasters, MD, PhD
University of Louisville, Louisville, KY

---

**Cancer Forum I – Signaling and Apoptosis**

3:30 - 5:30 pm

*Moderators: Daniel Albo, MD and James C. Cusack, Jr., MD*

**Nuclear Factor Kappa B Regulates Beta-Catenin Expression and Function in Human Colon Cancer Cells**

Christopher Smolock, MD
University of Pennsylvania, Philadelphia, PA

**Mechanisms of MET Dysregulation and Ligand-Dependency in Human Colorectal Cancer**

T. Francone, MD
Memorial Sloan-Kettering Cancer Center, New York, NY

**Expression of IL-8 in Pancreatic Tumor Cells is Regulated by a Src/STAT3**

Jose G. Trevino, MD
University of Texas M.D. Anderson Cancer Center, Houston, TX

**RON Tyrosine Kinase: A Novel Target for Enhancing Molecular Therapy in Colorectal Cancer**

Ashwani Rajput, MD
Roswell Park Cancer Institute, Buffalo, NY

**Escape from Endogenous Interferon Gamma Antitumor Effects by Alteration of IRF-1 and IRF-2 Responses**

B.D. Saunders, MD
University of Michigan, Ann Arbor, MI

**Tat-Bim Protein Induces Apoptosis in Cancer Cells**

Hiroyuki Kashiwagi, MD
Washington University, St. Louis, MD

**A Novel Small Molecule FAK Tyrosine Kinase Inhibitor Increases Apoptosis in Pancreatic Adenocarcinoma Cells**

Steven Hochwald, MD
University of Florida College of Medicine, Gainesville, FL

**Deregulation of JNK in Response to Chemotherapy When NF-KB is Inhibited: A Potential Target in Chemoresistant Pancreatic Cancers**

Hong Kin Kim, MD
University of North Carolina, Chapel Hill, NC

---

**Welcome Reception**

7:30 – 9:00 pm

Join us for hors d’oeuvres, refreshments and socializing. This complimentary event will be held at the San Diego Marriott Hotel and is open to all physician registrants and registered guests.
Meet the Professor Breakfasts
6:30 - 7:30 am

Registration Required • Fee: $35 • Limit: 25 per breakfast

To ensure your selection, please register as early as possible. Indicate your selection on the enclosed registration form.

B1 The Significance of Positive Margins in Sarcoma Surgery
Murray F. Brennan, MD

Nancy D. Perrier, MD

B3 Sentinel Lymph Node Mapping Aberrations and Challenges in Breast Cancer
Hiram S. Cody, III, MD

B4 Cryoblation of Breast Cancer – Technical Aspects
Rache M. Simmons, MD

B5 Preserving the Aesthetic Breast: Best Practices
Benjamin O. Anderson, MD
Grant W. Carlson, MD

B6 Laparoscopic Distal Pancreatectomy – Really?
Mitchell C. Posner, MD

B7 Melanoma – Optimal but Practical Nodal Management Strategies
Vernon K. Sondak, MD

B8 Surgical Education – What’s Next and What to Do About It
David P. Jaques, MD

Opening Announcements
7:30 - 7:45 am

Timothy J. Eberlein, MD, SSO President
Heidi Nelson, MD, Scientific Program Chairman
Robert M. Barone, MD, Local Arrangements Chairman

Presentations from James Ewing Oncology Fellowship Award Winners
7:45 - 8:00 am

J. Pablo Arnoletti, MD
Eric Nakakura, MD
Sophie Dessureault, MD

Plenary Session I
8:00 - 9:00 am

Moderator: Raphael E. Pollock, MD, PhD

Surgical Complications Associated with Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection, Versus SLND Alone in the American College of Surgeons Oncology Group (ACOSOG) Trial Z0011
Anthony Lucci, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment
Sam Wiseman, MD
St. Paul’s Hospital, University of British Columbia
Vancouver, Canada

Trends in the Treatment and Outcome of Pancreatic Cancer in the United States
Nancy Baxter, MD
University of Minnesota
Minneapolis, MN

An International, Randomized, Double-Blind, Phase 3 Study of the Specific Active Immunotherapy Agent, Onamelatucel-L (Canvaxin™), Compared to Placebo as a Post-Surgical Adjuvant in AJCC Stage IV Melanoma
Donald L. Morton, MD
John Wayne Cancer Institute
Santa Monica, CA
Plenary Session II
10:15 - 11:00 am
Moderator: Nicholas J. Petrelli, MD

Cyclin Dependent Kinase2-Associated Protein (CDK2-AP1) Expression and Modulation of Cell Growth and Apoptosis in Microsatellite-Unstable (MSI) Colorectal Cancer (CRC)
P.V. Sreeramoju, MD
Albert Einstein College of Medicine
New York, NY

Oxaliplatin Resistance in Colorectal Cancer Cells Induces Epithelial-to-Mesenchymal Transition
Anthony D. Yang, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

Clinical and Immunologic Responses in Cancer Patients with Stage IV Disease Treated with Autologous Tumor Cell-Based Vaccines Using a Universal GM-CSF Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L): Early Results
Sophie Dessureault, MD
H. Lee Moffitt Cancer Center
Tampa, FL

Annual Heritage Presentation Honoring Charles M. Balch, MD
SSO President 1991-92
11:00 - 11:15 am

Presented by:
Alfred M. Cohen, MD
Director and CEO, Markey Cancer Center
Lexington, KY

American Cancer Society/SSO Basic Science Lecture
Genomic Applications for the Diagnosis and Treatment of Cancer
11:15 am - 12:00 Noon

Bruce Stillman, PhD, FRS
President
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

Introduction by:
Steven F. Sener, MD
Past President, ACS

Lunch & Poster Session in Exhibit Area
Noon - 1:00 pm
Posters # P1 – P115 will be presented.
Parallel Sessions
1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

Gastrointestinal Cancer

Moderators: Malcolm M. Bilimoria, MD and Mokenge P. Malafa, MD

The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-Analysis
Douglas M. Iddings, MD
John Wayne Cancer Institute
Santa Monica, CA

Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, MTHFR or XRCC1 Gene?
D.Y. Kim, MD
Ajou University School of Medicine
Suwon, South Korea

Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nongram
Rebekah White, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Stromal Osteonectin Overexpression is Associated with Poor Outcome in Patients with Periampullary Cancer
Mark Bloomston, MD
Ohio State University, Columbus, OH

Better Survival in Esophageal Cancer Patients After Surgical Treatment in University Hospitals. A Plea for Performance by Surgical Oncologists
C. Verhoef MD
University Medical Center Groningen
Groningen, Netherlands

Single Nucleotide Polimorphisms (SNPs) in the Promoter Region of the E-Cadherin Gene in Young Patients with Diffuse Gastric Cancer
Heriberto Medina-Franco, MD
National Institute of Medical Sciences and Nutritio, Mexico City, Mexico

Pilot Study of Minimally Invasive Surgery for Gastric Cancer: Laparoscopic Assisted Distal Gastrectomy (LADG)
K. Koneri, MD, Kameda Medical Center
Kamogawa, Japan

Repeat Hepatectomy for Recurrent Colorectal Liver Metastasis: Analyses of Preoperative Prognostic Factors
Seiji Ishiguro, MD
National Cancer Center Hospital
Tokyo, Japan

Breast Cancer

Moderators: Robert J. Goulet, Jr., MD and Amy C. Degmin, MD

Prior Axillary Surgery is Not a Contraindication to Sentinel Lymph Node Biopsy: Results of Reoperative Sentinel Lymph Node Biopsy in 133 Patients
C. Garcia-Etienne, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Serumproteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage I Breast Cancer
Claudio Belluoco, M, University of Padova
Padova, Italy

Detecting Occult Breast Cancer in Prophylactic Mastectomies: Sentinel Node Biopsy vs. Pre-Operative MRI
D. Black, MD, Massachusetts General Hospital
Boston, MA

Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Disease at Presentation
E.L. Newman, MD, University of Michigan
Ann Arbor, MI

Initial Outcomes for Patients Treated on the American Society of Breast Surgeons Mammo Site Clinical Trial for Ductal Carcinoma In Situ of the Breast
Jacqueline S. Jeruss, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

Lymphedema Therapy Reduces the Volume of Edema and Pain in Breast Cancer Patients
John B. Hamner, MD
University of Tennessee, Memphis, TN

Prospective Randomized Trial Comparing Intradermal, Intraparenchymal, and Subareolar Injection Routes for Sentinel Lymph Node Mapping and Biopsy in Breast Cancer
Stephen P. Povoski, MD
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Comprehensive Cancer Center of The Ohio State University, Columbus, OH

Is Sentinel Node Biopsy in DCIS Necessary?
Thomas B. Julian, MD
NSABP Operations Office and Allegheny General Hospital
Pittsburgh, PA
Parallel Sessions
1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

**Melanoma**

*Moderators: Kenneth K. Tanabe, MD and Sandra L. Wong, MD*

**Role of Microphthalmia Transcription Factor in Melanoma Prognosis and Differentiation**
George I. Salti, MD
University of Illinois at Chicago
Chicago, IL

**Downregulation of Pro-Apoptosis Genes in an Early Event in the Progression of Malignant Melanoma**
Eric H. Jensen, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

**Role of BAY 43-9006 in Combination with Temozolomide and and Melphalan in Metastatic Melanoma**
Jin Yoo, MD
Duke University Medical Center
Durham, NC

**AJCC Nodal Factors and Microscopic Tumor Burden Predict Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients**
Robert H. Andtbacka, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

**Is the 10% Rule Appropriate for Sentinel Lymph Node Biopsy for Melanoma?**
H. Kroon, MD
University of Michigan
Ann Arbor, MI

**Patients (pts) Prognosis and Clinico-Pathological Factors Influencing False Negative (FN) Results of Sentinel Lymph Node (SLN) Biopsy in Cutaneous Melanoma (CM)**
Zhigui Liu. Nowecki, MD
Cancer Center – Institute
Warsaw, Poland

**Peri-Operative Adjuvant Biotherapy for Resected Cutaneous Melanoma: An Update on 5 Years of Follow-up**
John L. Zapas, MD
Franklin Square Hospital Center
Baltimore, MD

**Intraoperative Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma by Imprint Cytology**
V. Soo, MD
Wake Forest University
Winston-Salem, NC

**Endocrine/Head & Neck**

*Moderators: John A. Olson, Jr., MD and Ashok Shaha, MD*

**Survival Benefit of Extensive Hepatic Cytoreduction for Symptomatic Metastases from Neuroendocrine Tumors**
Farin F. Amersi, MD
John Wayne Cancer Institute
Santa Monica, CA

**Four-Dimensional Computed Tomography: A Novel Imaging Modality for Localization of Parathyroid Tumors**
S.E. Rodgers, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

**Is Tumor Size the Best Predictor of Outcome for Papillary Thyroid Cancer?**
Y. Cheema, MD
University of Wisconsin
Madison, WI

**Positron Emission Tomogram (PET) Detected Thyroid Incidentalomas: Need for Further Investigation?**
Chandrakanth Are, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

**New Parameters in Risk Stratification in Papillary Thyroid Carcinoma: Eosinophilic Infiltration, Glutathione S-Transferases and Genomic Instability**
Sadir Alrawi, MD
Roswell Park Cancer Institute
Buffalo, NY

**Photodynamic Therapy for Head and Neck Neoplasia Using Photofrin®**
Rosa E. Cuenca, MD
Leo Jenkins Cancer Center, Brody School of Medicine
East Carolina University
Greenville, NC
Cancer Forum II – Translational Research
1:00 - 3:00 pm

Moderators: Jeffrey F. Moley, MD and Timothy J. Yeatman, MD

Omega- Fatty Acids Prevent Early Pancreatic Neoplasia in EL-Kras Transgenic Mice
Laleh Golkar, MD
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Photodynamic Therapy for Treatment of Self-expandable Metal Stent Luminal Obstruction
Rosa E. Cuenca, MD
Leo Jenkins Cancer Center, Brody School of Medicine and Physics Department, East Carolina, Greenville, NC

Real-Time Intraoperative Imaging Using Invisible Near-Infrared Light
John V. Frangioni, MD
Beth Israel Deaconess Medical Center, Boston, MA

Dynamic Contrast Magnetic Resonance Imaging Detects Premalignant High-Grade Dysplasia in Epithelial Carcinogenesis Via Identification of Enhanced Microvascular Permeability
Jeffrey M. Arbeit, MD
Washington University in St. Louis, St. Louis, MO

Metastasis of Papillary Thyroid Carcinoma is Associated with BRAF Gene Mutation
Joseph Kim, MD
John Wayne Cancer Center, Santa Monica, CA

Imaging the Role of Spleenocytes in Promoting Liver Metastases
Michael Bouvet, MD
University of California San Diego, San Diego, CA

Correlation of Breast Cancer Protein and Gene Expression Profiles with ER Status
Susanna H. Shin, MD
Eastern Virginia Medical School, Norfolk, VA

Dynamic Contrast Magnetic Resonance Imaging Detects Premalignant High-Grade Dysplasia in Epithelial Carcinogenesis Via Identification of Enhanced Microvascular Permeability
Jeffrey M. Arbeit, MD
Washington University in St. Louis, St. Louis, MO

Poster Discussion Session (Posters #P1 – P115)
3:00 – 4:00 pm

This session will encourage meaningful discussion and constructive critique of recent research findings. Over 100 posters will be displayed. Authors will be present.

Symposium
What’s New in Ablative Therapies for Malignant Tumors
4:00 - 6:00 pm

Indications and Evidence for Radiofrequency Ablation of Liver Tumors
Anton Bilchik, MD
John Wayne Cancer Institute
Santa Monica, CA

Ablative Approaches to Pulmonary, Renal and Bone Tumors
Robert G. Martin, MD
University of Louisville
Louisville, KY

Microwave Ablation: The Next Modality?
David M. Mahvi, MD
University of Wisconsin
Madison, WI

Where Do We Go from Here? Improving Targeting and Monitoring of Ablative Therapy
Michael A. Choti, MD
Johns Hopkins University School of Medicine
Baltimore, MD

Case Presentations and Panel Discussion
Friday, March 24

Clinical Trials Highlights 2006
4:00 - 6:00 pm
Moderator: Margaret Mooney, MD

Introduction and Update on NCI Trial Priorities
Margaret Mooney, MD
National Cancer Institute
Bethesda, MD

Open Trials and New Concepts
Gastrointestinal Cancer Trials
Heidi Nelson, MD
Mayo Clinic, Rochester, MN
Nicholas J. Petrelli, MD
Helen F. Graham Cancer Center
Newark, DE

Thoracic Cancer Trials
Leslie Kohman, MD
SUNY Upstate Medical University
Syracuse, NY
Bryan Meyers, MD
Barnes Jewish Hospital
St. Louis, MO

Breast Cancer Trials
Kelly K. Hunt, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX
Terry Mamounas, MD, MPH
Aultman Cancer Center
Canton, OH

Panel Discussion

Saturday, March 25

Meet the Professor Breakfasts
6:45 - 7:45 am
Registration Required • Fee: $35 • Limit: 25 per breakfast
To ensure your selection, please register as early as possible. Indicate your selection on the enclosed registration form.

B9 Handoscopy: It’s a Role in Colectomy
Bob Cima, MD

B10 Adrenal Tumors – Interesting Cases and Best Approaches
Jeffrey E. Lee, MD

B11 The Role of Neoadjuvant Therapy
Esophageal Cancer
Stephen G. Swisher, MD

B12 Rectal Cancer Adjuvant, Who and When?
David A. Rothenberger, MD

B13 Rectal Cancer Sphincter Preservation Options
Timothy J. Yeatman, MD

B14 Colorectal Metastases – New Methods for Optimal Liver Resection
Bryan Clary, MD

B15 Breast Cancer – Neoadjuvant Practical Applications
Lisa A. Newman, MD
Plenary Session III
8:00 - 9:00 am
Moderator: William G. Cance, MD

Endoscopic Ultrasound-guided Fine Needle Aspiration of Visible Celiac Nodes is Essential for Determining Prognosis in Patients with Distal Esophageal Cancer: A Survival Analysis in 71 M1a Patients
Eric Frechetti, MD
Laval Hospital, Quebec, Canada

A Phase II Trial of Bevacizumab with or without Low-Dose Interferon-alpha in Patients with Metastatic Malignant Melanoma
Kimberly A. Varker, MD
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Feasibility of Sentinel Lymph Node in Differentiated Thyroid Carcinoma
Paolo Carcoforo, MD
Sant’Anna Hospital
Ferrara, Italy

Correlation of Bone Marrow Micrometastases with Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients
Igor Langer, MD
Swiss Multicenter Study Group Sentinel Lymph Node in Breast Cancer
Basel, Switzerland

James Ewing Lecture

Surgical Oncology in the Genome Era
9:00 – 9:45 am

James S. Economou, MD, PhD
Director, UCLA Human Gene Medicine Program, Deputy Director, UCLA Jonsson Comprehensive Cancer Center,
University of California at Los Angeles
Los Angeles, CA

Plenary Session IV
10:15 - 11:15 am
Moderator: Fabrizio Michelassi, MD

Factors Associated with Treatment Failure in T1bN0 Breast Cancer Patients
Timothy J. Kennedy, MD
Northwestern University
Chicago, IL

Phase II Study of Iminib Mesylate in Patients with Metastatic Medullary Thyroid Carcinoma (MTC): An Interim Analysis
Mark S. Cohen, MD
Washington University School of Medicine
Alvin J. Siteman Cancer Center
St. Louis, MO

EGF Pathway Activation in Hepatocellular Carcinoma is a Prognostic Predictor of Survival and a Potential Target for Biologic Therapy
Jason M. Foster, MD
Roswell Park Cancer Institute
Buffalo, NY

High-Resolution Positron Emission Tomography in Breast Cancer
Zandra H. Cheng, MD
Anne Arundel Medical Center
Annapolis, MD
John Wayne Clinical Research Lecture

Lessons Learned from 30 Years of Clinical Research

11:15 am - 12:00 Noon

Murray F. Brennan, MD
Chairman, Department of Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY

Lunch & Poster Session
in Exhibit Area
Noon - 1:00 pm

Posters # P116 – P230 will be presented.

Cancer Forum III – Immune and Gene Therapy

1:00 – 3:00 pm

Moderators: David C. Linehan, MD and George E. Peoples, Jr., MD

NBL1: A Novel Methylation Target in Colon Cancer
Quan P. Ly, MD
Moffitt Cancer Center & Research Institute
Tampa, FL

Creation and Validation of a Novel Herpes Simplex Virus with Diagnostic and Therapeutic Potential in Pancreatic Cancer
James J. Mezhib, MD
University of Chicago
Chicago, IL

Tumor Selective Vaccinia Mutant is Effective in the Treatment and Prevention of Peritoneal Carcinomatosis in a Mouse Model
Srîcharan Chalikonda, MD
Cleveland Clinic Foundation
Cleveland, OH

Involvement of Bcl Gene Family Members in Anti-4-1BB-Induced T Cell Survival and Antitumor Reactivity
Hidde M. Kroon, MD
University of Michigan
Ann Arbor, MI

Nanoscale Platform for Radioinducible Gene Therapy
Hank Schmidt, MD
University of Chicago
Chicago, IL

Targeting and Bioluminescence Imaging of a Novel Herpes Simplex Virus is Dependent on Tumor MEK Activity
Kerrington Smith, MD
University of Chicago
Chicago, IL

Activated Murine Liver Plasmacytoid Dendritic Cells are Able to Stimulate NK Cells and T Cells
T. Peter Kingham, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

The Therapeutic value of Protein Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins
Myron Arlen, MD
North Shore University Hospital
Manhasset, NY
Parallel Sessions
1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

**Gastrointestinal Cancer**

*Moderators: Philip B. Paty, MD and Jean-Nicolas Vauthey, MD*

- Armless Navigation and Image-guidance During Abdominal Exploration for Recurrent Colorectal Cancer
  
  *Ergun Kocak, MD*
  
  *Ohio State University, Columbus, OH*

- Adjuvant Radiation Therapy Improves Survival for Gallbladder Carcinoma
  
  *Pablo Mojica, MD*
  
  *City of Hope National Medical Center, Duarte, CA*

- Loss of MAL Expression in Precancerous (Dysplastic) Lesion of the Esophagus
  
  *Koshi Mimori, MD*
  
  *Medical Institute of Bioregulation, Kyushu University, Beppu, Japan*

- Gene Expression Profiling of Gastric Cancer Reveals a Lymph Node Metastatic Transcriptional Fingerprint
  
  *Claudio Belluco, MD*
  
  *University of Padova, Padova, Italy*

- Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction
  
  *Andrew P. Barbour, MD*
  
  *Memorial Sloan-Kettering Cancer Center, New York, NY*

- mTOR Inhibition Potentiates Cytotoxic Therapy Against Pancreatic Cancer Through Tumore Vessel Thrombosis and Inhibition of Hypoxia-Inducible Factor-1
  
  *Koji Fujimoto, MD*
  
  *Kyoto University, Kyoto, Japan*

- Recurrence of Pseudomyxoma Peritonei After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome
  
  *Robert Smeenk, MD*
  
  *The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands*

- Carcinoid of the Rectum Risk Stratification (CaRRS): A New Strategy for Preoperative Outcome Assessment
  
  *Bridget N. Fahy, MD*
  
  *Memorial Sloan-Kettering Cancer Center, New York, NY*

**Breast Cancer**

*Moderators: Kelly K. Hunt, MD and David J. Winchester, MD*

- Frequency of BRCA1 and BRCA2 Genomic Rearrangements and Mutations in Men with Breast Cancer: A Clinic-based Study in the United States
  
  *Julia Tchou, MD*
  
  *University of Pennsylvania, Philadelphia, PA*

- Lymph Node Metastatic Fingerprint Revealed by Genome-Wide Transcriptional Profiling of Primary Breast Cancer
  
  *Claudio Belluco, MD*
  
  *University of Padova, Padova, Italy*

- Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base
  
  *Christopher M. Pezzi, MD*
  
  *Abington Memorial Hospital, Abington, PA*

- Type and Duration of Exogenous Hormone Use Does Not Affect Receptor Status when Breast Cancers Develop
  
  *Anjali S. Kumar, MD*
  
  *University of California San Francisco, San Francisco, CA*

- How Many Sentinel Nodes Should be Removed in Breast Cancer?
  
  *Michael S. Sabel, MD*
  
  *University of Michigan, Ann Arbor, MI*

- Upstaging and Improved Survival of Early Breast Cancer Patients after Implementation of Sentinel Node Biopsy for Routine Axillary Staging
  
  *Kimberly Vanderveen, MD*
  
  *University of California – Davis, Sacramento, CA*

- Results of MRI Screening for Breast Cancer in High Risk Patients with LCIS and Atypical Ductal Hyperplasia
  
  *Elisa R. Port, MD*
  
  *Memorial Sloan-Kettering Cancer Center, New York, NY*

- Conflicts in Decision-Making for Breast Cancer Surgery
  
  *Diane M. Opatt, MD*
  
  *Fox Chase Cancer Center, Philadelphia, PA*
Parallel Sessions
1:00 - 3:00 pm
These sessions will feature abstract presentations specifically related to the following areas:

**Sarcoma**

*Moderators: Samuel Singer, MD and Sam S. Yoon, MD*

**Use of Tissue Expanders and Preoperative External Beam Radiotherapy in the Treatment of Retroperitoneal Sarcoma**
Jonathan S. White, MD
Tom Baker Cancer Centre
Calgary, Canada

**Neoadjuvant Gleevec is Effective in the Treatment of High-risk Gastrointestinal Stromal Tumors**
Cletus Arciero, MD
Fox Chase Cancer Center
Philadelphia, PA

**Retroperitoneal and Truncal Sarcomas: Prognosis Depends Upon Type Not Location**
E.A. Perez, MD
University of Miami
Miami, FL

**Outcome of Metastatic GIST in the Era Before Imatinib Mesylate**
Jason S. Gold, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

**A 30 Year Review of Primary Breast Sarcomas Evaluated at a Single Institution**
Ying Wei Lum, MD
Johns Hopkins
Baltimore, MD

**Lymph Drainage Pattern of the Peritoneal Space: Intraperitoneal Lymph Travels via Visceral Bowel Lymphatics to the Thoracic Duct**
Cherie P. Parungo, MD
Brigham & Women's Hospital
Boston, MA

**Hepatectomy and Lung Radiofrequency Ablation for Hepatic and Subsequent Pulmonary Metastases from Colorectal Carcinoma**
Tristan D. Yan, MD
St. George Hospital
Sydney, Australia

**Thoracosopic Localization’s Techniques for Patients with Lung Cancer**
Davide Sortini, MD
University of Ferrara
Ferrara, Italy

**Outcomes/Surgical Specialties**

*Moderators: Tara Breslin, MD and Larissa Temple, MD*

**Validation of a Predictive Model for Sentinel Lymph Node Metastases in Melanoma**
Michael S. Sabel, MD
University of Michigan
Ann Arbor, MI

**Size of Metastasis in the Sentinel Node Predicts Additional Nodal Involvement in Penile Carcinoma**
Bin Kroon, MD
The Netherlands Cancer Institute
Amsterdam, Netherlands

**DOD Award: Phase I Trial of Anti-prostate Cancer Therapy via Anti-PSMA Designer T Cell Autografting**
Richard P. Junghans, MD
Boston University School of Medicine
Roger Williams Medical Center
Providence, RI

**Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer**
Marianne K. Lange, MD
Spectrum Health/Michigan State University
Grand Rapids, MI

**Advanced Generation Anti-CEA Designer T Cell Therapy of Adenocarcinoma**
Richard P. Junghans, MD
Boston University School of Medicine
Roger Williams Medical Center
Providence, RI

**Impact of Surgical Palliation on Quality of Life in Patients with Advanced Malignancy: Results of the Decision and Outcome in Palliative Surgery (DOPS) Trial**
Yale D. Podnos, MD
City of Hope National Medical Center
Duarte, CA

**A Systematic Review of Deep Venous Thrombosis Prophylaxis in Cancer Patients: Implications for Improving Quality**
Michael J. Leonard, MD
UCLA, Los Angeles, CA

**Teaching Palliation and End of Life Care: A Core Curriculum for Surgical Residents**
D.D. Klaristenfeld, MD
Brown University
Providence, RI
Poster Discussion Session (Posters #P116 – P230)

3:00 – 4:00 pm

This session will encourage meaningful discussion and constructive critique of recent research findings.
Over 100 posters will be displayed. Authors will be present.

Clinical Affairs Committee Program

The Role of Neoadjuvant Therapy: New Perspectives and Strategies

4:00 - 5:30 pm

Moderator: Martin J. Heslin, MD

Neoadjuvant Therapy for Operable Breast Cancer: Pitfalls and Possibilities
Kelly K. Hunt, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

Rectal Cancer: Future of Neoadjuvant Strategies
Nipun Merchant, MD
Vanderbilt University Medical Center
Nashville, TN

Neoadjuvant Therapy in Extremity Sarcoma
Peter W.T. Pisters, MD
University of Texas M.D. Anderson Cancer Center
Houston, TX

Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Safety and Efficacy of Focused Dose Escalation
Martin J. Heslin, MD
University of Alabama
Birmingham, AL

Discussion
Cine Clinic
4:00 - 5:30 pm
Moderator: N. Joseph Espat, MD

Laparoscopic Resection of a Large Mucocele with Malignant Potential
Ron G. Landmann, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Laparoscopic Splenic Preserving Distal Pancreatectomy
John H. Wang, MD
SUNY Stony Brook
Stony Brook, NY

Laparoscopic Assisted Distal Gastrectomy with Lymph-Node Dissection for Early Gastric Cancer
Hisakazu Hoshi, MD
Kameda Medical Center
Kamogawa, Japan

A Combined Endoscopic and Laparoscopic Endoluminal Surgical Resection of a Proximal Gastric Gastrointestinal Stromal Tumor
Eric Wallace, MD
University of Iowa
Iowa City, IA

Laparoscopic Palliation of Metastatic Gastric Cancer
Stephanie Dunkle-Blatter, MD
Geisinger Medical Center
Danville, PA

Annual SSO Business Meeting
5:30 - 6:30 pm

I. Call to Order – Timothy J. Eberlein, MD
II. President’s Report – Timothy J. Eberlein, MD
• Recognition of Program Chair
• Announce Resident Essay Winners
III. Secretary’s Report – Fabrizio Michelassi, MD
• In Memoriam
• Introduction of New Members
IV. Treasurer’s Report – William G. Cance, MD
V. Annals of Surgical Oncology Charles M. Baleb, MD
VI. Recognition of Outgoing Councillors Timothy J. Eberlein, MD
VII. Nominating Committee Report John M. Daly, MD
VIII. Introduction of New President
IX. New Business – Raphael E. Pollock, MD, PhD
• 2007 Annual Meeting – Washington, D.C.
X. Adjourn – Raphael E. Pollock, MD, PhD

SSO President’s Reception and Banquet
7:00 - 10:00 pm
Registration Required • Black Tie Optional

All physicians and their registered guests are invited to attend this gala event honoring SSO President Timothy J. Eberlein, MD.
Also honored will be this year’s James Ewing Layman’s Award winner.
Expanding the Criteria for Hepatic Resection: Are Old Criteria Obsolete?
Yuman Fong, MD
Professor Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY

Multimodal Therapy in Downstaging Hepatic Metastases and Improving Resectability
Jean-Nicolas Vauthey, MD
Professor of Surgery
University of Texas M.D. Anderson Cancer Center
Houston, TX

A New Era of Effective Chemotherapeutic and Biologic Agents in Metastatic Colorectal Cancer
Lee Rosen, MD
Premiere Oncology and the John Wayne Cancer Institute
Santa Monica, CA

Tailoring Chemotherapy in Metastatic Colorectal Cancer Using Molecular Profiling. Are We There Yet?
Robert Diasio, MD
Professor Medical Oncology,
University of Alabama
Birmingham, AL

Discussion

Clinical Update in Colon Cancer
9:00 – 11:00 am
Moderator: Elin Sigurdson, MD

Introduction
Elin Sigurdson, MD

Primary Prevention and Screening for Colorectal Cancer in the General Population
Monica M. Bertagnolli, MD
Brigham and Women’s Hospital
Boston, MA

Screening and Management of Patients with a Familial Risk for Colorectal Cancer
Jose G. Guillem, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Management of the Malignant Polyp in the Colon and Rectum
Santhat Nivatvongs, MD
Mayo Clinic
Rochester, MN

Prognosis of the Patient with Colon Cancer
Hartley S. Stern, MD
University of Ottawa
Ottawa, Canada

Adjourn – 11:00 am